![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Incyte Ceases Trial of Metastatic Colorectal Cancer Candidate
Incyte Ceases Trial of Metastatic Colorectal Cancer Candidate
Biopharmaceutical company Incyte has ceased its Phase 2 study of its metastatic colorectal cancer and high C-reactive protein candidate.
The trial — which studied Jakafi in combination with regorafenib compared with placebo — failed to show a sufficient level of efficacy in the high CRP subgroup to warrant continuation, the Wilmington, Del.-based drugmaker said.
Jakafi is also in a late-stage trial for the treatment of pancreatic cancer.
Upcoming Events
-
21Oct